bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 2029: Investigation of anti-tumor activity of porcine myeloperoxidase for urothelial carcinoma of the bladder
Authors: Liu Junnan , Allen Robert C. , Stephens Jackson T. , Shah Paras , Huang Haojie 
Published: March 2024

Abstract
Introduction: Porcine myeloperoxidase (pMPO) is a cationic enzyme secreted by granulocytic leukocytes capable of selectively binding cancer cells due to their negative surface charge. In the presence of hydrogen peroxide (H2O2) and sodium chloride (NaCl), MPO catalyzes the production of electronically excited singlet molecular oxygen, which exerts focused cytotoxic activity against cancer cells.
Methods: Human bladder non-cancer (SV-HUC1) and cancer cells (T24 and 5637) were used to assess differential cytotoxic activity of pMPO. pMPO was combined with associated reagents, including H2O2, NaCl, and L-proline and glycine for 45 minutes to support the generation of singlet oxygen. MTS assay was used to assessed cell viability at day 3 post-treatment. Non-cancer and cancer cells were labeled with GFP and mCherry, respectively, via infection with lentivirus and cultured in tandem to allow for simultaneous treatment of both cell types. After the treatment, flow cytometry and microscopy were used to monitor the growth of the cells.
Results: No cytotoxicity was noted when SV-HUC1 cells were cultured with individual reagents pMPO, NaCl, L-Proline, or Glycine, and limited cytotoxicity was observed with H2O2. Notably, cell viability was nearly maximally preserved for SV-HUC1 cells. The combination of pMPO with associated reagents resulted in killing of 5637 and T24 cells, with tumoricidal activity maintained across increasing tumor cell density, with cell viability preserved for SV-HUC1 cells. Within the cell co-culture system, simultaneous treatment of both cell types with the pMPO treatment resulted in selective killing of tumor cells and preservation of SV-HUC1 cells. Mechanistic studies confirm specificity of pMPO binding to tumor cells, and further, high levels of expression of gammaH2AX and phospho-ATM in 5637 and T24 cells following treatment.
Conclusion: pMPO demonstrates selective and efficient killing of bladder cancer cells with minimal cytotoxicity against non-cancer urothelial cells. Given its reliance on direct surface contact with tumor cells for activity, pMPO may be developed as an intravesical therapy for treatment of non-muscle invasive bladder cancers.
Acknowledgements: This work was partially supported by Mayo funds provided to Dr. Haojie Huang.
Citation Format: Junnan Liu, Robert C. Allen, Jackson T. Stephens, Paras Shah, Haojie Huang. Investigation of anti-tumor activity of porcine myeloperoxidase for urothelial carcinoma of the bladder [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2029.
Abstract 2046: Targeting cellular models of glioblastoma versus non-target and off-target cell populations using U87-MG membrane lipid-modified nanoliposomes
Authors: Janton Kaylee , Baamir Duha , Patel Aesha , Boco Sheren , Campbell Robert 
Published: March 2024

Abstract
Background: Glioblastoma Multiform (GBM) is an aggressive and malignant form of brain cancer known for its invasiveness and significant heterogenicity. The majority of GBM cases are linked to genetic mutations (ie. TP53, EGFR, and PTEN), which disrupt the normal regulation of cell growth and division, resulting in uncontrolled cell proliferation. The utilization of nanoparticles presents a promising approach for addressing the complexities associated with selective drug delivery to GMB and treatment. The purpose of this study was to investigate the effect of including U87-MG membrane lipid extracts in nanoliposomes using target, non-target, and normal healthy cellular populations in vitro.
Methods: The nanoliposomes employed for the experiments included various ratios of U87-MG lipid extracts (lipids derived from U87-MG cells), DOPC, Cholesterol, and DPPE-Rhodamine for fluorescence studies. The particle size and zeta potential values were measured and monitored throughout for consistency. Fluorescence intensity values (arbitrary units) were used to assess extent of cell binding, and uptake at the various time points. In vitro studies were employed to evaluate the cellular uptake activity of U87-MG-modified nanoliposome preparations using mixed ratios and compositions of lipid materials. Cell lines employed were, LN-18 (human glioma), T98G (human glioma), U87-MG (human glioma), 4TI (murine breast), and HBEC-5i (normal healthy) cells.
Results: The average size for the nanoliposomes (with and without lipid extract) fell within the range of 110 to 220 nm, while the zeta potential for the CLENs was negatively-charged. In vitro studies revealed that the inclusion of U87MG lipid extract in nanoliposomes increased cellular uptake in glioma cells when compared to control. Current investigations focus on different microenvironments, including non-target and off target cell populations. The findings from the cellular uptake analyses to date suggest that the in vitro cellular uptake of the CLENs varied in accordance with the total lipid extract content for all cell lines.
Citation Format: Kaylee Janton, Duha Baamir, Aesha Patel, Sheren Boco, Robert Campbell. Targeting cellular models of glioblastoma versus non-target and off-target cell populations using U87-MG membrane lipid-modified nanoliposomes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2046.
Abstract 2059: An image-based real time method to measure antibody-dependent cellular phagocytosis
Authors: Wang Jianyong , Shi Yongchang , Sun Yonglian , Koerber James T. , Seki Akiko , Rutz Sascha 
Published: March 2024

Abstract
Antibody-dependent cellular phagocytosis (ADCP) is an important mechanism of action of therapeutic antibodies. In vitro quantification of macrophage phagocytosis has been technically challenging. Flow cytometry assays were traditionally used for ADCP activity measurements, these methods were static measurements at certain time point, thus provide no information about engulfment kinetics. Moreover, the flow cytometry assays require lifting the macrophage cells from the labware which may affect macrophage activities. We have developed a real time ADCP assay using a live cell analysis system. The target cells labeled with a pH sensitive dye only fluoresce when they are engulfed in acidic phagosomes in the presence of specific antibodies. Our assay is a plate-based with a simple mix and read protocol without disturbing the macrophages. The new method is quantitative and robust, can be readily used for high-throughput screening for functional antibodies. By studying the ADCP activities of different subtypes of macrophages, we found M2 microphages showed the strongest ADCP activity compare to M0 and M1 macrophages, due to their different expression levels of FcgRs. The assay is highly sensitive to differentiate the antibody variants with enhanced Fc function. It can also be used to study the kinetics and mechanisms of ADCP.
Citation Format: Jianyong Wang, Yongchang Shi, Yonglian Sun, James T. Koerber, Akiko Seki, Sascha Rutz. An image-based real time method to measure antibody-dependent cellular phagocytosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2059.
Abstract 2064: Unveiling the correlation between gemtuzumab-ozogamicin efficacy and CD33+ expression in AML primary samples using the novel AML vitroscreen
Authors: Gilardi Mara , Kaushik Garima , Walling Brandon , Schiavini Paolo , Cairo Stefano , Zipeto Marianna 
Published: March 2024

Abstract
Acute myeloid leukemia (AML) poses a significant therapeutic challenge, with a rising incidence in recent times. This clonal hematopoietic disorder of progenitor and stem cells exhibits aggressive behavior, and despite initial remission, recurrence is common1. The conventional shift from chemotherapy to monoclonal antibodies and antibody-drug conjugates (ADCs) has been hindered by the absence of AML-specific antigens. Notably, CD33, expressed strongly in 80-90% of AML cells, has become a target for gemtuzumab-ozogamicin (Mylotarg), the sole FDA approved ADC for AML treatment2. While advancements in understanding AML molecular mechanisms have influenced clinical approaches, the lack of clinically representative models hinders therapeutic progress. Existing models, both in vivo and ex vivo, struggle to capture the heterogeneity and complexity of AML3. Addressing this, we present our proprietary assay, Champions AML VitroScreen®4, designed for testing therapeutic candidates in primary AML samples. Our diverse bank of deeply characterized AML samples encompasses multiple subtypes, allowing evaluation of therapeutic responses through cell viability, proliferation, and clonal composition analyses. To validate our novel assay, we employed the VitroScreen platform to test Mylotarg across various AML subtypes, considering CD33 expression levels. By assessing more than 20 AML models, we determined the IC50 for Mylotarg and observed dose-dependent responses, where sensitivity to the drugh correlated with CD33 expression. Through multiple endpoints, including viability, proliferation, apoptosis, and phenotyping, we categorized primary AML models as responders, low responders, or resistant, establishing a strong positive correlation between Mylotarg sensitivity and CD33 expression. Our innovative approach, utilizing deeply characterized AML patient samples in the AML VitroScreen® platform, facilitates high-throughput drug testing. This system, serving as an ideal clinical translational setting in preclinical research, holds promise for developing tailored therapeutic strategies. Ultimately, this approach could significantly impact patient outcomes by offering improved strategies for both primary and recurrent AML cases.
Citation Format: Mara Gilardi, Garima Kaushik, Brandon Walling, Paolo Schiavini, Stefano Cairo, Marianna Zipeto. Unveiling the correlation between gemtuzumab-ozogamicin efficacy and CD33+ expression in AML primary samples using the novel AML vitroscreen [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2064.
Abstract 2071: Pre-clinical evidence for new camptothecin-peptide conjugates in the treatment of sortilin-positive colorectal cancers
Authors: Das Sanjoy , Currie Jean-Christophe , Demeule Michel , Charfi Cyndia , Zgheib Alain , Nayyar Amit , Nguyen Anh Minh Thao , Danalache Bogdan Alexandru , Beliveau Richard , Marsolais Christian , Annabi Borhane 
Published: March 2024

Abstract
Limitations in current colorectal cancer (CRC) camptothecin (CPT)-based chemotherapy have mostly been attributed to low specificity and high systemic cytotoxic side effects. More effective therapies are therefore required to improve the clinical outcomes of patients with CRC. Here, we developed a selective and better anticancer drug delivery of CPT through conjugation to a peptide (TH19P01) that targets Sortilin (SORT1), a scavenging receptor expressed in various tumor tissues including CRC. In the current study, significant SORT1 expression was detected in various CRC cell lines as well as that of irinotecan analogs efflux pump (ABCG2) in LoVo and HT-29 cells. Considering this result, we used our proprietary peptide conjugation SORT1 technology to increase cell targeting selectivity and cell delivery efficacy of CPT analogs. Different peptide drug conjugates (PDCs) were generated linking the TH19P01 peptide to SN-38 (an irinotecan metabolite) or exatecan, which are two main CPT derivatives used in recent antibody drug conjugates (ADC) as payloads. In vitro, immunonofluorescent microscopy revealed that TH19P01 was rapidly internalized (&lt;15 min) in a SORT1-positive human HT-29 CRC cell model. These PDCs also inhibited CRC cell proliferation at low nM concentrations (3-90 nM). In vivo, weekly administration of TH2101 (SN-38) and of TH2303 (exatecan) conjugates were well tolerated as they had little impact on mouse body weight but caused a more potent growth inhibition of the HT-29 CRC tumor xenograft model than did either unconjugated irinotecan or exatecan molecules. In fact, at their maximum tolerable dose, irinotecan and exatecan caused a tumor growth inhibition of only 48% and 45% whereas TH2101 and TH2303 inhibited the growth of HT-29 tumors by 83% and 91%, respectively. These results provide strong pre-clinical evidence for the future development of novel CPT PDCs therapeutics with targeting of SORT1-positive CRC cells.
Citation Format: Sanjoy Das, Jean-Christophe Currie, Michel Demeule, Cyndia Charfi, Alain Zgheib, Amit Nayyar, Anh Minh Thao Nguyen, Bogdan Alexandru Danalache, Richard Beliveau, Christian Marsolais, Borhane Annabi. Pre-clinical evidence for new camptothecin-peptide conjugates in the treatment of sortilin-positive colorectal cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2071.
Abstract 2128: Surufatinib treatment in pancreatic cancer: unveiling the role of GPR34 in TAMs and enhancing immunotherapy efficacy
Authors: Guo Xiaofan , Liu Yuxiao , Song Yuning , Huang Jing , Zhu Wenbo , Xu Peijun , Yu Jun , Gao Song , Hao Jihui 
Published: March 2024

Abstract
Background: Pancreatic cancer, often resistant due to its immunologically "cold" nature and tumor-associated macrophages (TAMs), presents challenges in chemotherapy and immunotherapy. This study uses single-cell transcriptomics to assess TAM subsets in response to surufatinib, an inhibitor targeting CSF-1R, FGFR1, and VEGFR1-3.
Methods: Surufatinib-treated patient samples were analyzed using single-cell RNA sequencing to identify altered macrophage subsets. Additional techniques, such as flow cytometry, tissue microarrays, co-culture assays, and macrophage-specific knockout mice, were used for further study. Western blot and immunofluorescence clarified the molecular functions of TAMs, and the impact of targeting these TAMs on PD-1 therapy was evaluated in a pancreatic cancer mouse model.
Results: Single-cell RNA sequencing revealed macrophage subsets with increased GPR34 expression following surufatinib treatment. The Gpr34fl/flLYZ2Cre mouse orthotopic-transplanted tumor model, treated with gemcitabine and albumin-bound paclitaxel, showed significantly reduced tumor growth compared to the control group, with notably lower percentages of exhausted T (Tex) cells and regulatory T (Treg) cells, and a significant increase in cytotoxic T cells in tumor tissue. LysoPS, produced by chronically injured pancreatic cancer cells, promotes the differentiation of bone marrow-derived monocytes (BMDM) into an immunosuppressive phenotype, an effect abolished after siGpr34 transfection. The LysoPS-GPR34 axis can significantly activate the NF-κB signaling pathway in BMDMs, potentially inducing the senescence-related secretory phenotype (SASP) and contributing to the macrophages' immunosuppressive phenotype. Combining a GPR34 antagonist with αPD-1 and PD-L1 inhibitors significantly curbed tumor growth and enhanced the immune environment in KPC mice.
Conclusions: Elevated GPR34 in TAMs enhances immunosuppression via the NF-κB pathway, affecting T cell distribution. GPR34's role could be key in optimizing surufatinib treatment for pancreatic cancer, indicating new therapeutic avenues.
Citation Format: Xiaofan Guo, Yuxiao Liu, Yuning Song, Jing Huang, Wenbo Zhu, Peijun Xu, Jun Yu, Song Gao, Jihui Hao. Surufatinib treatment in pancreatic cancer: unveiling the role of GPR34 in TAMs and enhancing immunotherapy efficacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2128.
Abstract 2175: Multiple exposures to antibiotics and increased risk of colorectal cancer
Authors: Jani Niti , Richardson Maredith , Hogan Kristen , Pena Maria M. 
Published: March 2024

Abstract
Colorectal cancer (CRC) is the second leading cause of cancer related deaths in the United States and worldwide. In 2023, approximately 153,020 individuals will be diagnosed with CRC and 52,550 will die, including 19,550 cases and 3750 deaths in patients under 50 years of age. CRC in younger patients (less than 55 years) is known as early onset colorectal cancer (EOCRC). It is a growing global phenomenon whose incidence and mortality has incidence from 11% to 20% between 1995 to 2019 and is expected to increase by 140% by 2030. While it has been linked to known and established risks for CRC, the underlying causes and mechanisms are poorly understood. Based on our current knowledge of the disease, we propose that EOCRC results from exposure of children and young adults to exposome factors that have been increasing globally in the last four decades that may impact the microbiome causing dysbiosis and inflammation in the distal colon and rectum, the anatomical site of EOCRC. Among the likely factors is the use of antibiotics, particularly in infants and children. In this study we hypothesized that early life exposure to antibiotics causes dysbiosis and inflammation in the distal colon and rectum leading to increased mutations and epigenetic events that promote EOCRC development. Specifically, we examined the effect of the most commonly prescribed pediatric antibiotics on the gut microbiota and inflammatory environment in the colon, and their impact on tumor development upon exposure to a carcinogen. We treated A/J mice with multiples rounds of antibiotics and then exposed them to azoxymethane, a carcinogen to determine the effect on tumor development in the colon. The results showed that antibiotic exposure caused dysbiosis and inflammation in the colon of antibiotic treated mice as well as systemic inflammation in mice treated with antibiotics. Treatment with azoxymethane, a carcinogen in the presence of antibiotic-induced dysbiosis led to increased tumor burden in the distal colon. These results suggest a possible involvement of antibiotics on increased risk of EOCRC.
Citation Format: Niti Jani, Maredith Richardson, Kristen Hogan, Maria M. Pena. Multiple exposures to antibiotics and increased risk of colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2175.
Abstract 2186: Bacterial lung cancer therapeutics from soil bacteria in New York City
Authors: Deb Dhruba , Danino Tal 
Published: March 2024

Abstract
The microbiome's diverse functions in human health have generated increasing interest in using live bacteria for cancer therapy. Due to their natural presence in colon, lung and breast tissue, bacterial therapies have been augmented using synthetic biology in order to treat infections, inflammation, and cancer. One major challenge is finding safe and effective host species and therapeutic payloads for a particular type of cancer. Here we explored the vast diversity of microbial isolates in the environment as a valuable source of novel therapeutic compounds that can be expressed by bacteria. Specifically, we isolated and identified soil bacteria from 25 local parks, and investigated their secreted compounds for anti-cancer activity using monolayer and 3D-spheroid cultures of lung cancer. Through metagenomic analysis, toxicology assays, varied growth conditions, and bacteria-cancer co-culture experiments, we found Bacillus spp. isolates from Manhattan parks' soil that secreted products with high, dose-dependent cytotoxicity against lung cancer models. We also demonstrate that Bacillus subtilis, a model organism for gram-positive bacteria, can colonize lung cancer tumor spheroids, pointing to its use as a viable strain for bacteria cancer therapy. The work presented here underscores the potential of harnessing environmental microbial diversity for the development of gram positive species and their compounds as cancer therapeutics.
Citation Format: Dhruba Deb, Tal Danino. Bacterial lung cancer therapeutics from soil bacteria in New York City [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2186.
Abstract 2247: Cellular senescence as a potential mechanism underlying differences in chemoresistance between lung cancer cell lines derived from African-American and Caucasian patients
Authors: Semenova Nina , Robertson Camille C. , Yakisich Juan S. , Ayscue Robyn R. , Iyer Anand K. , Azad Neelam 
Published: March 2024

Abstract
Lung cancer remains the leading cause of cancer-related deaths world-wide. Statistical data reveals significant difference in both lung cancer incidence and death rate between African-American (AA) and Caucasian (CA) populations in the United States. Although these disparities can be partially attributed to socio-economical reasons, the biological mechanisms underlying them are poorly understood. In this study, we compared the chemoresistance of cell lines derived from tumor tissues obtained from AA patients (H23, H292) versus CA patients (A549, H460). The cell lines were treated with FDA-approved anti-cancer drugs as well as with cardenolide analogues previously reported by our group to have anti-cancer properties. Irrespectively of drug class, cellular senescence appeared to develop more abundantly in cells derived from AA patients. However, AA-derived cell lines manifested higher drug resistance in comparison to CA-derived ones, especially to cardenolide analogues. Recovery experiments in drug-free media revealed faster and more efficient re-growth after long-term (2 weeks) drug treatment in AA-derived cell lines. Taken together, the data provides a potential role for cellular senescence as mechanism of the differential chemoresistance observed between AA and CA lung cancer cell lines, revealing new potential targets for anti-cancer therapy.
Citation Format: Nina Semenova, Camille C. Robertson, Juan S. Yakisich, Robyn R. Ayscue, Anand K. Iyer, Neelam Azad. Cellular senescence as a potential mechanism underlying differences in chemoresistance between lung cancer cell lines derived from African-American and Caucasian patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2247.